Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Financials Momentum Sentiment Forecast Dividends Due Diligence

Diagnostics & Research is Zen Rated B and is the 56th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Revenue	EBITDA	Earnings	EPS	Rev. Y/Y	Rev. 5Y	Earn. Y/Y	Earn. 5Y	Earnings Date
CDNA	CAREDX INC	$1.11B	$412.82M	$4.48M	-$8.19M	-$0.16	19.17%	13.29%	N/A	N/A
ILMN	ILLUMINA INC	$20.76B	$4.34B	$1.46B	$850.00M	$5.47	-0.66%	6.04%	N/A	4.07%
TMO	THERMO FISHER SCIENTIFIC INC	$174.37B	$45.20B	$11.65B	$6.85B	$18.22	5.36%	4.72%	6.61%	-1.88%
SHC	SOTERA HEALTH CO	$4.41B	$1.16B	$439.93M	$77.95M	$0.27	5.74%	7.30%	68.75%	N/A
LH	LABCORP HOLDINGS INC	$21.08B	$13.95B	$2.22B	$876.50M	$10.54	7.25%	-0.04%	18.56%	-8.00%
IQV	IQVIA HOLDINGS INC	$26.77B	$16.31B	$3.49B	$1.36B	$7.91	5.87%	7.50%	4.49%	40.21%
BLLN	BILLIONTOONE INC	$3.56B	$305.11M	$19.76M	$2.92M	$0.18	99.97%	N/A	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$179.81M	$79.12M	-$4.69M	-$8.12M	-$0.76	8.47%	3.12%	N/A	N/A
MTD	METTLER TOLEDO INTERNATIONAL INC	$25.75B	$4.03B	$1.24B	$869.19M	$42.17	3.98%	5.47%	3.69%	10.81%
PRPO	PRECIPIO INC	$55.19M	$24.05M	$1.46M	-$363.00k	-$0.23	29.77%	31.60%	N/A	N/A
A	AGILENT TECHNOLOGIES INC	$32.36B	$7.07B	$1.82B	$1.29B	$4.55	8.14%	5.02%	4.12%	11.59%	2026-05-27
NTRA	NATERA INC	$29.38B	$2.31B	-$200.34M	-$208.16M	-$1.52	35.90%	42.61%	N/A	N/A
DGX	QUEST DIAGNOSTICS INC	$21.33B	$11.28B	$2.19B	$1.02B	$9.17	11.03%	1.76%	14.48%	-7.29%
DHR	DANAHER CORP	$123.97B	$24.78B	$7.09B	$3.69B	$5.19	4.02%	-0.02%	0.00%	-4.31%
IDXX	IDEXX LABORATORIES INC	$45.18B	$4.30B	$1.51B	$1.06B	$13.17	10.42%	9.72%	22.28%	14.07%	2026-05-05
NEO	NEOGENOMICS INC	$1.23B	$745.97M	-$26.06M	-$99.21M	-$0.76	10.95%	10.44%	N/A	N/A	2026-05-05
CAI	CARIS LIFE SCIENCES INC	$5.22B	$812.03M	$16.97M	-$537.96M	-$3.22	96.97%	N/A	N/A	N/A
NEOG	NEOGEN CORP	$2.07B	$870.54M	-$442.39M	-$608.78M	-$2.80	-3.92%	14.10%	N/A	N/A
RVTY	REVVITY INC	$9.69B	$2.86B	$763.29M	$241.20M	$2.07	3.67%	1.41%	-6.33%	-20.50%	2026-05-05
BDSX	BIODESIX INC	$109.23M	$88.50M	-$21.88M	-$35.27M	-$4.67	24.08%	14.20%	N/A	N/A
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$8.16B	$4.02B	$408.66M	-$144.34M	-$2.91	-0.85%	6.55%	N/A	N/A	2026-05-07
MEDP	MEDPACE HOLDINGS INC	$11.92B	$2.68B	$609.92M	$460.40M	$16.22	24.19%	22.90%	20.06%	29.35%
MYGN	MYRIAD GENETICS INC	$448.84M	$824.50M	-$323.20M	-$365.90M	-$3.95	-1.56%	8.16%	N/A	N/A
WAT	WATERS CORP	$30.13B	$3.17B	$1.03B	$642.63M	$10.80	6.99%	6.00%	0.47%	5.15%	2026-05-05
CSTL	CASTLE BIOSCIENCES INC	$737.63M	$344.23M	$11.34M	-$24.16M	-$0.83	3.66%	40.60%	N/A	N/A	2026-05-11
ICLR	ICON PLC	$8.62B	$8.10B	$1.21B	$599.48M	$7.42	-2.46%	24.01%	-18.10%	4.17%
QGEN	QIAGEN NV	$7.43B	$2.09B	$717.27M	$424.88M	$1.96	5.65%	2.25%	415.79%	3.88%	2026-05-06
TWST	TWIST BIOSCIENCE CORP	$3.70B	$391.56M	-$50.92M	-$76.58M	-$1.27	18.59%	31.10%	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$364.72M	$85.33M	-$95.75M	-$74.90M	-$0.20	-6.24%	-9.19%	N/A	N/A	2026-05-12
RDNT	RADNET INC	$4.41B	$2.04B	$278.12M	-$18.65M	-$0.25	11.51%	13.74%	N/A	N/A
BIAF	BIOAFFINITY TECHNOLOGIES INC	$9.85M	$6.16M	-$14.32M	-$14.91M	-$8.66	-34.18%	N/A	N/A	N/A
STIM	NEURONETICS INC	$138.34M	$149.16M	-$27.12M	-$39.00M	-$0.59	99.17%	24.81%	N/A	N/A	2026-05-12
PRE	PRENETICS GLOBAL LTD	$287.20M	$92.39M	-$33.89M	-$37.71M	-$2.68	479.76%	7.23%	N/A	N/A
GH	GUARDANT HEALTH INC	$11.49B	$982.02M	-$373.91M	-$416.28M	-$3.32	32.88%	27.92%	N/A	N/A
MDXH	MDXHEALTH SA	$10.58M	$107.88M	-$3.14M	-$33.52M	-$6.70	19.80%	42.34%	N/A	N/A	2026-05-14
PSNL	PERSONALIS INC	$604.77M	$69.65M	-$69.66M	-$81.27M	-$0.91	-17.69%	-2.40%	N/A	N/A
XWEL	XWELL INC	$10.15M	$29.21M	-$15.18M	-$28.23M	-$5.08	-13.83%	28.35%	N/A	N/A
XGN	EXAGEN INC	$73.60M	$66.58M	-$12.50M	-$19.95M	-$0.93	19.65%	9.66%	N/A	N/A
GRAL	GRAIL INC	$2.11B	$147.17M	-$378.16M	-$408.35M	-$11.11	17.18%	N/A	N/A	N/A	2026-05-12
ISPC	ISPECIMEN INC	$4.17M	$1.93M	-$8.95M	-$10.49M	-$91.00	-79.24%	-25.10%	N/A	N/A
FLGT	FULGENT GENETICS INC	$401.30M	$320.35M	-$57.01M	-$73.81M	-$2.39	9.54%	-16.16%	N/A	N/A
VNRX	VOLITIONRX LTD	$19.26M	$1.73M	-$21.61M	-$23.36M	-$4.40	40.04%	164.15%	N/A	N/A	2026-05-13
ACRS	ACLARIS THERAPEUTICS INC	$477.80M	$7.83M	-$64.47M	-$64.92M	-$0.53	-58.19%	3.84%	N/A	N/A	2026-05-07
OPK	OPKO HEALTH INC	$830.60M	$581.12M	-$34.69M	-$212.92M	-$0.27	-15.71%	-19.96%	N/A	N/A	2026-05-12
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$134.46M	$4.06M	-$47.92M	-$50.22M	-$1.65	115.58%	27.24%	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$11.38M	$43.79M	-$13.11M	-$37.38M	-$2.00	-28.87%	-15.56%	N/A	N/A
DRIO	DARIOHEALTH CORP	$53.29M	$22.36M	-$35.45M	-$61.74M	-$10.12	-17.31%	24.17%	N/A	N/A
SERA	SERA PROGNOSTICS INC	$74.76M	$81.00k	-$30.49M	-$31.93M	-$0.67	5.19%	26.51%	N/A	N/A	2026-05-13
NOTV	INOTIV INC	$10.66M	$514.03M	$23.78M	-$69.37M	-$2.00	8.19%	51.02%	N/A	N/A	2026-05-07
BNBX	BNB PLUS CORP	$2.70M	$2.05M	-$31.42M	-$70.57M	-$143.56	-25.64%	-6.77%	N/A	N/A
MBAI	CHECK-CAP LTD	$10.18M	$0.00	$4.15M	$4.14M	$0.66	N/A	N/A	N/A	N/A
ADVB	ADVANCED BIOMED INC	$5.70M	$0.00	$4.56M	$4.39M	$3.80	N/A	N/A	N/A	N/A
QUCY	MAINZ BIOMED NV	$5.14M	$537.08k	-$14.94M	-$16.21M	-$2.70	-39.92%	1.70%	N/A	N/A
NDRA	ENDRA LIFE SCIENCES INC	$6.14M	$0.00	-$6.87M	-$7.03M	-$8.93	N/A	N/A	N/A	N/A
FONR	FONAR CORP	$124.10M	$106.03M	$15.32M	$7.07M	$1.15	4.39%	4.61%	-1.71%	1.26%	2026-05-14

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #1 top diagnostic & research stock out of 55 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 34, which is 5 points higher than the diagnostic & research industry average of 29.

CDNA passed 11 out of 33 due diligence checks and has average fundamentals. Caredx has seen its stock return 42.67% over the past year, overperforming other diagnostic & research stocks by 29 percentage points.

Caredx has an average 1 year price target of $24.50, an upside of 13.95% from Caredx's current stock price of $21.50.

Caredx stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Caredx, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #2 top diagnostic & research stock out of 55 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: A, and AI: B.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 36, which is 7 points higher than the diagnostic & research industry average of 29.

ILMN passed 12 out of 33 due diligence checks and has average fundamentals. Illumina has seen its stock return 77.47% over the past year, overperforming other diagnostic & research stocks by 64 percentage points.

Illumina has an average 1 year price target of $147.13, an upside of 8.36% from Illumina's current stock price of $135.78.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Illumina, 37.5% have issued a Strong Buy rating, 12.5% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 12.5% have issued a Strong Sell.

3. Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) is the #3 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Thermo Fisher Scientific (NYSE:TMO) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: C, and AI: B.

Thermo Fisher Scientific (NYSE:TMO) has a Due Diligence Score of 33, which is 4 points higher than the diagnostic & research industry average of 29.

TMO passed 12 out of 38 due diligence checks and has average fundamentals. Thermo Fisher Scientific has seen its stock return 11.75% over the past year, underperforming other diagnostic & research stocks by -2 percentage points.

Thermo Fisher Scientific has an average 1 year price target of $659.73, an upside of 40.6% from Thermo Fisher Scientific's current stock price of $469.21.

Thermo Fisher Scientific stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Thermo Fisher Scientific, 81.82% have issued a Strong Buy rating, 18.18% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.69%, which is 1 percentage points higher than the diagnostic & research industry average of 0.86%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 35.6% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.13%, which is the same as the diagnostic & research industry average of 0.86%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 27.3% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.88%, which is the same as the diagnostic & research industry average of 0.86%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.28% in the last day, and down -0.55% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 100, which is 87 points higher than the diagnostic & research industry average of 13. It passed 7 out of 7 valuation due diligence checks.

Icon's stock has dropped -22.28% in the past year. It has underperformed other stocks in the diagnostic & research industry by -36 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 30 points higher than the diagnostic & research industry average of 13. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -18.84% in the past year. It has underperformed other stocks in the diagnostic & research industry by -32 percentage points.

3. Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 14, which is 1 points higher than the diagnostic & research industry average of 13. It passed 1 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has gained 11.75% in the past year. It has underperformed other stocks in the diagnostic & research industry by -2 percentage points.

Are diagnostic & research stocks a good buy now?

51.16% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 28.47% over the next year.

4.44% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 24.44% of diagnostic & research stocks are rated B (Buy), 51.11% are rated C (Hold), 20% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 18.11x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Caredx (NASDAQ:CDNA)

2. Illumina (NASDAQ:ILMN)

3. Thermo Fisher Scientific (NYSE:TMO)

1. Quest Diagnostics (NYSE:DGX)

2. Labcorp Holdings (NYSE:LH)

3. Agilent Technologies (NYSE:A)

1. Icon (NASDAQ:ICLR)

2. Qiagen Nv (NYSE:QGEN)

3. Thermo Fisher Scientific (NYSE:TMO)

Company

Stock Tools

Stock Ideas